Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Malignant Melanoma [Tafinlar and Mekinist (Wave 2)] | LaunchTrends | US | 2014

Login to access report north_east
Contact sales account_box

LaunchTrends: Tafinlar and Mekinist is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Tafinlar (GlaxoSmithKline’s dabrafenib) and Mekinist (GlaxoSmithKline’s trametinib).
LaunchTrends: Tafinlar and Mekinist measures the impact of these new agents on the unresectable and metastatic melanoma market following launch. The study surveys medical oncologists from the United States and conducts qualitative interviews with physicians. This report evaluates physicians’ current awareness and perception of Tafinlar and Mekinist and Tafinlar and Mekinist combination therapy relative to other currently available therapies for unresectable and metastatic melanoma, current and anticipated usage of Tafinlar, Mekinist, and Tafinlar/Mekinist combination therapy, and promotional activity of Tafinlar and Mekinist.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east